Adaptive Design Theory and Implementation Using SAS and R, Second Edition (Chapman & Hall/CRC Biostatistics Series)

Chang, Mark

ISBN 10: 1138034231 / ISBN 13: 9781138034235

Editore: Chapman and Hall/CRC, 2016

Riguardo questo articolo

2nd edition NO-PA16APR2015-KAP.

Codice articolo 26390151636

Dati bibliografici

• Titolo: Adaptive Design Theory and Implementation Using SAS and R, Second Edition (Chapman & Hall/CRC Biostatistics Series)
• Editore: Chapman and Hall/CRC
• Data di pubblicazione: 2016
• Lingua: Inglese
• ISBN 10: 1138034231
• ISBN 13: 9781138034235
• Rilegatura: Brossura
• Edizione: seconda edizione
• Condizione: New

Descrizione articolo

Riassunto

Get Up to Speed on Many Types of Adaptive Designs

Since the publication of the first edition, there have been remarkable advances in the methodology and application of adaptive trials. Incorporating many of these new developments, Adaptive Design Theory and Implementation Using SAS and R, Second Edition offers a detailed framework to understand the use of various adaptive design methods in clinical trials.

New to the Second Edition

• Twelve new chapters covering blinded and semi-blinded sample size reestimation design, pick-the-winners design, biomarker-informed adaptive design, Bayesian designs, adaptive multiregional trial design, SAS and R for group sequential design, and much more
• More analytical methods for K-stage adaptive designs, multiple-endpoint adaptive design, survival modeling, and adaptive treatment switching
• New material on sequential parallel designs with rerandomization and the skeleton approach in adaptive dose-escalation trials
• Twenty new SAS macros and R functions
• Enhanced end-of-chapter problems that give readers hands-on practice addressing issues encountered in designing real-life adaptive trials

Covering even more adaptive designs, this book provides biostatisticians, clinical scientists, and regulatory reviewers with up-to-date details on this innovative area in pharmaceutical research and development. Practitioners will be able to improve the efficiency of their trial design, thereby reducing the time and cost of drug development.

Informazioni sull?autore

Chang, Mark